CMND - Clearmind Medicine Inc. Common Shares

https://www.clearmindmedicine.com

Momentum: Bearish

Recent News

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

GlobeNewswire • 1 month, 3 weeks ago • score: 0.19

Vancouver, Canada, July 23, 2025 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( "Clearmind" or the "Company" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...

Bullish

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

GlobeNewswire • 2 months ago • score: 0.24

Vancouver, Canada, July 15, 2025 ( GLOBE NEWSWIRE ) -- Clearmind Medicine Inc. ( Nasdaq: CMND ) , ( FSE: CWY0 ) ( "Clearmind" or the "Company" ) , a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Clearmind Medicine Inc., a preclinical pharmaceutical company, develops new psychedelic drugs to treat neglected health problems. The company is headquartered in Vancouver, Canada.

52W High

$2.18

52W Low

$0.80

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-1.24

Valuation

As of 2025-04-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.79

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.41

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

2.80%

Institutions (25–75% balanced)

10.96%

Shares Outstanding

5,379,400

Float

5,224,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-04-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.12

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.39%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0076

0.0092

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025